Status:
COMPLETED
Generic Plerixafor Efficacy of Autologous Hematopoietic Stem Cell Transplantation
Lead Sponsor:
Hospital Universitario Dr. Jose E. Gonzalez
Conditions:
Lymphoma
Myeloma
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
Generic plerixafor use at reduced-dose for mobilization on HSCT transplant
Detailed Description
The objective of this study is to demonstrate that the use of a low dose of the generic form of a drug called plerixafor is effective in increasing the amount of hematopoietic cells (stem cells) in yo...
Eligibility Criteria
Inclusion
- Patients with lymphoma or multiple myeloma who are candidates for autoHSCT
- Patients \> 18 years old who signed our informed consent
- Normal CBC count (Hb \> 10, WBC 4.0-11.00, plt \> 100,000)
Exclusion
- Patients with HIV, Hepatitis C, Hepatitis B diagnosis
- Pregnant women
Key Trial Info
Start Date :
December 9 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 30 2020
Estimated Enrollment :
6 Patients enrolled
Trial Details
Trial ID
NCT06892119
Start Date
December 9 2019
End Date
November 30 2020
Last Update
March 27 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Universidad Autónoma de Nuevo León
Monterrey, Nuevo León, Mexico, 64460